首页> 外文会议>IEEE International Ultrasonics Symposium >Ultrasound-triggered and targeted gene delivery by using cationic microbubbles to enhance GDNF gene transfection in a rat Parkinson's disease model
【24h】

Ultrasound-triggered and targeted gene delivery by using cationic microbubbles to enhance GDNF gene transfection in a rat Parkinson's disease model

机译:通过使用阳离子微气泡增强GDNF基因在大鼠帕金森病模型中的转染来触发超声和靶向基因传递

获取原文

摘要

Glial cell line-derived neurotrophic factor (GDNF) is a potent agent for treating Parkinson's disease (PD). Microbubbles (MBs) have been exploited as a carrier for GDNF delivery with focused ultrasound (FUS) destruction. However, GDNF supplementation only relieves PD symptoms rather than cure it. Thus, design of an endogenous GDNF generative mechanism is an urgent concern for novel PD treatment. Here, we synthesized a cationic MBs (cMBs) with high GDNF plasmid (GDNFp) binding to achieve blood-brain barrier disruption (BBBD) with FUS, and currently enhance the GDNFp transfection for PD therapy. PD lesions were established by implanting 6-hydroxydopamine into left brain of rats. A 1-MHz FUS (0.7 MPa, duty factor = 5 %, PRF = 1 Hz, sonication time = 90 s) was sonicated at striatum and substantia nigra after GcMBs injection. Sites of gene expression were confirmed by firefly luciferase gene-loaded cMBs (LcMBs) with bioluminescence imaging, individually. The motor behavior and dopamine (DA) levels of the treated rats were traced to estimate treatment outcome. Result showed that the positively charge of cMBs (+39.48 ± 9.28 mV) made them significant for DNA binding. With FUS, GcMBs provided sufficient BBBD area for enhanced gene transfection in PD lesion. Bioluminescence data showed that the released Luc-gene expressed started from 24 h after treatment. The GDNF level of PD rats restored following the combing treatment (66.6 % of recovery). The treatment reduced rotations by 92.2 ± 5.7%, and improved of DA levels by 164.9 ± 1.23%. This study confirmed that GcMBs with FUS provides a novel strategy for local gene therapy in PD rats.
机译:胶质细胞源性神经营养因子(GDNF)是治疗帕金森氏病(PD)的有效药物。微泡(MBs)已被用作具有聚焦超声(FUS)破坏的GDNF输送的载体。但是,GDNF补充只能缓解PD症状,而不能治愈。因此,内源性GDNF生成机制的设计是新型PD治疗的迫切关注。在这里,我们合成了具有高GDNF质粒(GDNFp)结合力的阳离子MBs(cMBs),以实现FUS的血脑屏障破坏(BBBD),目前增强了PD治疗的GDNFp转染。通过将6-羟基多巴胺植入大鼠左脑来建立PD病变。注射GcMBs后,在纹状体和黑质处超声处理1 MHz的FUS(0.7 MPa,占空因数= 5%,PRF = 1 Hz,超声处理时间= 90 s)。基因表达的位点由萤火虫荧光素酶基因加载的cMBs(LcMBs)分别通过生物发光成像确认。追踪治疗大鼠的运动行为和多巴胺(DA)水平,以估计治疗效果。结果表明,cMBs的正电荷(+39.48±9.28 mV)使它们对于DNA结合具有重要意义。使用FUS,GcMBs提供了足够的BBBD区域,以增强PD病变中的基因转染。生物发光数据表明,释放的Luc基因表达从处理后24小时开始。精梳治疗后,PD大鼠的GDNF水平恢复(恢复的66.6%)。治疗使旋转减少了92.2±5.7%,DA水平提高了164.9±1.23%。这项研究证实,带有FUS的GcMBs为PD大鼠提供了一种新的局部基因治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号